Penso L, Dray-Spira R, Weill A, et al. - Researchers investigated differences, if any, in the risk of serious infections between biologic or targeted exposures in patients with psoriasis. From the National Health Data System covering nearly 99% of the French population, data were retrieved for this nationwide cohort study. Eligible patients were all adults with psoriasis, defined as receiving at least 2 prescriptions of a topical vitamin D derivative within a 2-year period, registered in the database between January 1, 2008, and May 31, 2019. Overall they included 44,239 new users of biologics in this cohort study. Findings revealed a higher risk of serious infections for new users of adalimumab or infliximab vs etanercept, whereas ustekinumab was linked with a lower risk of a serious infection. No increased risk of serious infections was evident for new users of secukinumab, ixekizumab, brodalumab, guselkumab, or apremilast vs etanercept, but an elevated risk of serious infections was observed with the use of concomitant nonsteroidal anti-inflammatory drugs or systemic corticosteroids. In light of these results, physicians may be able choose a biologic for patients with psoriasis who are at risk of serious infections.